{
    "id": 25455,
    "fullName": "RET G810A",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RET G810A lies within the protein kinase domain of the Ret protein (UniProt.org). G810A has been demonstrated to confer drug resistance (PMID: 31118272) and in the context of KIF5B-RET in culture (PMID: 27496134), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 15288,
                    "pubMedId": 31118272,
                    "title": "Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31118272"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5979,
        "geneSymbol": "RET",
        "terms": [
            "RET",
            "CDHF12",
            "CDHR16",
            "HSCR1",
            "MEN2A",
            "MEN2B",
            "MTC1",
            "PTC",
            "RET-ELE1"
        ]
    },
    "variant": "G810A",
    "createDate": "10/06/2016",
    "updateDate": "03/08/2020",
    "referenceTranscriptCoordinates": {
        "id": 125305,
        "transcript": "NM_020975",
        "gDna": "chr10:g.43119567G>C",
        "cDna": "c.2429G>C",
        "protein": "p.G810A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8726,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited growth of transformed cells over-expressing RET G810A in the context of KIF5B-RET in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 26416,
                "profileName": "KIF5B - RET RET G810A"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8718,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RET G810A in the context of KIF5B-RET conferred resistance to Caprelsa (vandetanib) in transformed cells in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 26416,
                "profileName": "KIF5B - RET RET G810A"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14428,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ofev (nintedanib) inhibited growth of transformed cell expressing RET G810A in the context of KIF5B-RET in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 26416,
                "profileName": "KIF5B - RET RET G810A"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8725,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over-expressing RET V804L in the context of KIF5B-RET demonstrated increased sensitivity to Lenvima (lenvatinib) in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 26416,
                "profileName": "KIF5B - RET RET G810A"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8724,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over-expressing RET G810A in the context of KIF5B-RET demonstrated increased sensitivity to Iclusig (ponatinib) in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 26416,
                "profileName": "KIF5B - RET RET G810A"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26415,
            "profileName": "RET G810A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26416,
            "profileName": "KIF5B - RET RET G810A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 125305,
            "transcript": "NM_020975",
            "gDna": "chr10:g.43119567G>C",
            "cDna": "c.2429G>C",
            "protein": "p.G810A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 125306,
            "transcript": "NM_020630",
            "gDna": "chr10:g.43119567G>C",
            "cDna": "c.2429G>C",
            "protein": "p.G810A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}